G
George S. Vassiliou
Researcher at University of Cambridge
Publications - 166
Citations - 13192
George S. Vassiliou is an academic researcher from University of Cambridge. The author has contributed to research in topics: Myeloid leukemia & Leukemia. The author has an hindex of 41, co-authored 143 publications receiving 10295 citations. Previous affiliations of George S. Vassiliou include Wellcome Trust Sanger Institute & Boston Children's Hospital.
Papers
More filters
Journal ArticleDOI
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.
E. Joanna Baxter,Linda M. Scott,Peter J. Campbell,Clare L. East,Nasios Fourouclas,Soheila Swanton,George S. Vassiliou,Anthony J. Bench,Elaine M. Boyd,Natasha Curtin,Michael A. Scott,Wendy N. Erber,Anthony R. Green,Anthony R. Green +13 more
TL;DR: A single acquired mutation of JAK2 was noted in more than half of patients with a myeloproliferative disorder and its presence in all erythropoietin-independent erythroid colonies demonstrates a link with growth factor hypersensitivity, a key biological feature of these disorders.
Journal ArticleDOI
Promoter-bound METTL3 maintains myeloid leukaemia by m 6 A-dependent translation control
Isaia Barbieri,Konstantinos Tzelepis,Luca Pandolfini,Junwei Shi,Gonzalo Millán-Zambrano,Samuel Robson,Demetrios Aspris,Valentina Migliori,Andrew J. Bannister,Namshik Han,Etienne De Braekeleer,Hannes Ponstingl,Alan G. Hendrick,Christopher R. Vakoc,George S. Vassiliou,Tony Kouzarides +15 more
TL;DR: Together, these data define METTL3 as a regulator of a chromatin-based pathway that is necessary for maintenance of the leukaemic state and identify this enzyme as a potential therapeutic target for acute myeloid leukaemia.
Journal ArticleDOI
Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study
Peter J. Campbell,Linda M. Scott,Georgina Buck,Keith Wheatley,Clare L. East,Joanne T Marsden,Audrey Duffy,Elaine M. Boyd,Anthony J. Bench,Michael A. Scott,George S. Vassiliou,Donald Milligan,Steve Smith,Wendy N. Erber,David Bareford,Bridget S. Wilkins,John T. Reilly,Claire N. Harrison,Anthony R. Green,Anthony R. Green +19 more
TL;DR: The results suggest that JAK2 V617F-positive essential thrombocythaemia and polycythaemia vera form a biological continuum, with the degree of erythrocytosis determined by physiological or genetic modifiers.
Journal ArticleDOI
Prediction of acute myeloid leukaemia risk in healthy individuals
Sagi Abelson,Grace Collord,Grace Collord,Stanley W.K. Ng,Omer Weissbrod,Netta Mendelson Cohen,Elisabeth Niemeyer,Noam Barda,Philip C. Zuzarte,Lawrence E. Heisler,Yogi Sundaravadanam,Robert Luben,Shabina Hayat,Ting Ting Wang,Ting Ting Wang,Zhen Zhao,Iulia Cirlan,Trevor J. Pugh,Trevor J. Pugh,Trevor J. Pugh,David Soave,Karen Ng,Calli Latimer,Claire Hardy,Keiran Raine,David T. Jones,Diana Hoult,Abigail Britten,John Douglas Mcpherson,Mattias Johansson,Faridah Mbabaali,Jenna Eagles,Jessica Miller,Danielle Pasternack,Lee Timms,Paul M. Krzyzanowski,Philip Awadalla,Rui Costa,Eran Segal,Scott V. Bratman,Scott V. Bratman,Scott V. Bratman,Philip A. Beer,Sam Behjati,Sam Behjati,Inigo Martincorena,Jean C.Y. Wang,Jean C.Y. Wang,Jean C.Y. Wang,Kristian M. Bowles,Kristian M. Bowles,J. Ramón Quirós,Anna Karakatsani,Carlo La Vecchia,Antonia Trichopoulou,Elena Salamanca-Fernández,José María Huerta,Aurelio Barricarte,Ruth C. Travis,Rosario Tumino,Giovanna Masala,Heiner Boeing,Salvatore Panico,Rudolf Kaaks,Alwin Krämer,Sabina Sieri,Elio Riboli,Paolo Vineis,Matthieu Foll,James McKay,Silvia Polidoro,Núria Sala,Kay-Tee Khaw,Roel Vermeulen,Peter J. Campbell,Peter J. Campbell,Elli Papaemmanuil,Elli Papaemmanuil,Mark D. Minden,Amos Tanay,Ran D. Balicer,Nicholas J. Wareham,Moritz Gerstung,Moritz Gerstung,John E. Dick,John E. Dick,Paul Brennan,George S. Vassiliou,George S. Vassiliou,Liran I. Shlush,Liran I. Shlush +90 more
TL;DR: Deep sequencing is used to analyse genes that are recurrently mutated in AML to distinguish between individuals who have a high risk of developing AML and those with benign ARCH, providing proof-of-concept that it is possible to discriminate ARCH from pre-AML many years before malignant transformation.
Journal ArticleDOI
A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid Leukemia
Konstantinos Tzelepis,Hiroko Koike-Yusa,Etienne De Braekeleer,Yang Li,Emmanouil Metzakopian,Oliver M. Dovey,Annalisa Mupo,Vera V. Grinkevich,Meng Li,Milena Mazan,Malgorzata Gozdecka,Shuhei Ohnishi,Jonathan L. Cooper,Miten Patel,Thomas McKerrell,Bin Chen,Ana Domingues,Paolo Gallipoli,Sarah A. Teichmann,Hannes Ponstingl,Ultan McDermott,Julio Saez-Rodriguez,Julio Saez-Rodriguez,Brian J. P. Huntly,Francesco Iorio,Cristina Pina,George S. Vassiliou,George S. Vassiliou,Kosuke Yusa +28 more
TL;DR: KAT2A inhibition demonstrated anti-AML activity by inducing myeloid differentiation and apoptosis, and suppressed the growth of primary human AMLs of diverse genotypes while sparing normal hemopoietic stem-progenitor cells.